Takeda receives positive chmp opinion for maribavir for the treatment of adults with post-transplant cytomegalovirus (cmv) refractory (with or without resistance) to prior therapies

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced the european medicines agency's (ema) committee for medicinal products for human use (chmp) has recommended the approval of maribavir for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a hematopoietic stem cel
TAK Ratings Summary
TAK Quant Ranking